Navigation Links
Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
Date:1/5/2012

WALTHAM, Mass. and TUCSON, Ariz., Jan. 5, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. and Ventana Medical Systems, Inc. announced that the companies have entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax's proprietary lead molecule entinostat. 

"Syndax is pleased to partner with Ventana, a world leader and innovator of tissue-based diagnostic solutions for patients worldwide, as we advance the development of entinostat in NSCLC," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "In ENCORE 401, a randomized, phase 2 study comparing erlotinib plus entinostat to erlotinib plus placebo, the subset of patients with tumors expressing high levels of the protein E-cadherin experienced a more favorable overall survival and we therefore intend to select this patient population in the confirmatory study planned to start in the second half of the year." 

Data from ENCORE 401 presented most recently at the 2011 World Conference on Lung Cancer indicated that a subset of advanced non-small cell lung cancer patients expressing high levels of the protein e-cadherin in their tumors derived a 4-month survival advantage with the combination treatment versus erlotinib plus placebo (HR 0.35 [95% CI:0.13-0.92] p=0.03).

In 2010, Ventana developed and launched an in vitro diagnostic kit for use on VENTANA platforms to measure levels of E-cadherin in epithelial tissues.  Ventana plans to validate the assay in its own in-house CAP/ CLIA certified laboratory and may then serve as the central laboratory for the upcoming Syndax clinical trial.

"We are very pleased to be the companion diagnostic partner of choice for Syndax to collaborate on this important project," said Ventana President, Mara G. Aspinall. "The plan to develop a companion diagnostic for entinostat shows that our companies are aligned in their commitment to advancing personalized healthcare to improve the lives of patients afflicted with cancer."

About Entinostat
Syndax's lead product entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. Entinostat is differentiated from other members of the class through its unique selectivity profile, pharmacokinetic properties and safety profile. Entinostat has been studied in more than 600 cancer patients where objective tumor responses have been observed in both solid and hematologic malignancies. Randomized, placebo-controlled phase 2 studies with entinostat have demonstrated promising results in combination with aromatase inhibitors in breast cancer (ENCORE 301) and with the EGFR-TKI erlotinib (ENCORE 401) in non-small cell lung cancer.  Results from the ENCORE clinical program have provided the basis for moving entinostat in pivotal, phase 3 testing across a platform of breast and lung cancer indications.

About Syndax
Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, late-stage, oncology-focused pharmaceutical company. The company is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Syndax has worldwide rights to develop and commercialize entinostat which has shown promise in randomized clinical trials in solid tumors and in phase 2 clinical trials in Hodgkin's lymphoma. Syndax is backed by top-tier venture capital firms Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. Formed in 2005, Syndax's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. For more information please visit www.syndax.com.

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's "Smart Systems" – intuitive, integrated staining and workflow management platforms that optimize laboratory efficiencies to reduce errors – support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving personalized medicine through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. Visit www.ventana.com to learn more.

VENTANA is a trademark of Roche.

Syndax Contact Information
E. Blair Schoeb 
Phone: 908.277.0386                                                                     
Email: bschoeb@syndax.com

VMSI Media Relations
Jacqueline Bucher
Phone: 520-877-7288
Email: jacquie.bucher@ventana.roche.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Survival Benefit With Syndax Pharmaceuticals Entinostat Maintained in Women with Advanced Breast Cancer
2. Multiple Data Presentations on Syndax Pharmaceuticals Entinostat at Upcoming Scientific Conferences
3. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
4. Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences
5. Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
6. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
7. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
8. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
9. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
10. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
11. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... SPRINGS, Florida , May 25, 2016 ... Business Conference & Expo earlier this month, the numbers ... As revenues continue to climb into the billions, more ... the newly released 4th Edition State of Legal Marijuana ... Frontier, a cannabis-focused data-analysis firm, much of the increase ...
(Date:5/25/2016)... ReportsnReports.com adds "Chronic Cough ... provides an overview on therapeutic pipeline of Chronic ... therapeutics assessment by drug target, mechanism of action ... along with latest updates, and featured news and ... in the therapeutic development for Chronic Cough and ...
Breaking Medicine Technology:
(Date:5/25/2016)... , ... May 25, 2016 , ... According to an ... type of hernia mesh that would effectively fight against common bacteria and protect against ... the healing process from hernia repair surgery even safer and could further ...
(Date:5/25/2016)... ... 25, 2016 , ... The Horizon Foundation for New Jersey ... to improve oral health-related awareness, education, prevention and treatment for young people. The ... promote best practices in 10 New Jersey counties where dental health needs among ...
(Date:5/25/2016)... ... , ... The Bank of America Charitable Foundation has awarded a grant to ... pathway to employment and successful careers in healthcare. On Wednesday, May 4th, Rick Bridwell, ... CEO of Medisend, parent organization and home of the General Myers Veterans Program. ...
(Date:5/25/2016)... ... 25, 2016 , ... Today American University of Antigua (AUA) ... announced the AUA-FIU Global MD Program. Students in the Global MD Program ... a Certificate of Completion from the FIU Herbert Wertheim College of Medicine Clinical ...
(Date:5/25/2016)... ... May 25, 2016 , ... Dr. Travis Schwarz is an experienced dentist who ... O’Fallon, MO 63366. He serves patients of all ages with a full menu of ... success is reflected in the superior patient reviews that he has consistently earned during ...
Breaking Medicine News(10 mins):